JPWO2020132066A5 - - Google Patents

Info

Publication number

JPWO2020132066A5

JPWO2020132066A5 JP2021531128A JP2021531128A JPWO2020132066A5 JP WO2020132066 A5 JPWO2020132066 A5 JP WO2020132066A5 JP 2021531128 A JP2021531128 A JP 2021531128A JP 2021531128 A JP2021531128 A JP 2021531128A JP WO2020132066 A5 JPWO2020132066 A5 JP WO2020132066A5

Authority

JP

Japan

Prior art keywords

antigen binding

seq

amino acid

binding molecule

acid sequence

Prior art date

2022-12-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims description 112
• 102000036639 antigens Human genes 0.000 claims description 112
• 108091007433 antigens Proteins 0.000 claims description 112
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 72
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 18
• 210000004027 cell Anatomy 0.000 claims description 12
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 11
• 239000003814 drug Substances 0.000 claims description 11
• 238000000034 method Methods 0.000 claims description 11
• 229940124597 therapeutic agent Drugs 0.000 claims description 11
• 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims description 10
• 239000002246 antineoplastic agent Substances 0.000 claims description 8
• 229940034982 antineoplastic agent Drugs 0.000 claims description 8
• 102000044389 human CD22 Human genes 0.000 claims description 7
• 206010028980 Neoplasm Diseases 0.000 claims description 6
• 230000001939 inductive effect Effects 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 6
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
• 150000001413 amino acids Chemical class 0.000 claims description 4
• 239000000611 antibody drug conjugate Substances 0.000 claims description 4
• 229940049595 antibody-drug conjugate Drugs 0.000 claims description 4
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
• 201000011510 cancer Diseases 0.000 claims description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
• 230000000694 effects Effects 0.000 claims description 4
• 239000013604 expression vector Substances 0.000 claims description 4
• 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 4
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
• 238000000338 in vitro Methods 0.000 claims description 4
• 230000036210 malignancy Effects 0.000 claims description 4
• 150000007523 nucleic acids Chemical class 0.000 claims description 4
• 102000039446 nucleic acids Human genes 0.000 claims description 4
• 108020004707 nucleic acids Proteins 0.000 claims description 4
• 230000002062 proliferating effect Effects 0.000 claims description 4
• 238000000159 protein binding assay Methods 0.000 claims description 4
• 238000001959 radiotherapy Methods 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
• 108010002350 Interleukin-2 Proteins 0.000 claims description 2
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
• 241000282567 Macaca fascicularis Species 0.000 claims description 2
• 230000010782 T cell mediated cytotoxicity Effects 0.000 claims description 2
• 230000003213 activating effect Effects 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 239000002773 nucleotide Substances 0.000 claims description 2
• 125000003729 nucleotide group Chemical group 0.000 claims description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 2
• 210000004881 tumor cell Anatomy 0.000 claims description 2
• 230000003827 upregulation Effects 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 11
• 238000002955 isolation Methods 0.000 claims 2
• 238000012986 modification Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2